Thomas Rasmussen

VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation.

Chr. Hansen Holding A/S is a bioscience company engaged in the development of natural solutions for the food, nutritional, pharmaceutical, and agricultural industries. It operates through the following segments: Food Cultures & Enzymes and Health & Nutrition. The Food Cultures & Enzymes segment is focused on producing and selling the cultures, enzymes, and probiotic products that help determine the taste, flavor, texture, shelf life, nutritional value, and health benefits of consumer products in the food industry. The Health & Nutrition segment is involved in the manufacturing and distribution of products for the dietary supplement, over-the-counter pharmaceutical, infant formula, animal feed, and plant protection industries. The company was founded by Christian Ditlev Ammentorp Hansen in 1874 and is headquartered in Horsholm, Denmark.

Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark.

Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies.